Advanced pancreatic cancer: The use of the apparent diffusion coefficient to predict response to chemotherapy

British Journal of Radiology

Volumn 82, Issue 973, 2009, Pages 28-34

  Niwa, T ^a,d   Ueno, M ^b   Ohkawa, S ^b   Yoshida, T ^a   Doiuchi, T ^a   Ito, K ^a   Inoue, T ^c  

^a Department of Radiology ^*  (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GIMERACIL; OTERACIL POTASSIUM; TEGAFUR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PREDICTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 58849164458     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/43911400     Document Type: Article

References (31)

1. Philip PA. Gemcitabine and platinum combinations in pancreatic cancer. Cancer 2002;95:908-11.
2. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-7.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
4. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
5. Bernhard H, Jager Arand E, Bernhard G, Heike M, Klein O, Riemann JF, et al. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. Br J Cancer 1995;71:102-5.
6. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7.
7. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006;107:676-85.
8. Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 2006;11:612-23.
9. Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-D-glu-cose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2005;32:389-97.
10. Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM, et al. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres AJNR Am J Neuroradiol 1995;16:361-71.
11. Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol. 2003;45:208-13.
12. Roth Y, Tichler T, Kostenich G, Ruiz Cabello J, Maier SE, Cohen JS, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology. 2004;232:685-92.
13. Lemaire L, Howe FA, Rodrigues LM, Griffiths JR. Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo. MAGMA 1999;8:20-6.
14. Gauvain KM, McKinstr RC, Mukherjee P, Perry A, Neil JJ, Kaufman BA, et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 2001;177:449-54.
15. Dzik Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360:307-8.
16. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177-83.
17. Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007;188:1001-8.
18. UICC TMN Classification of Malignant Tumours. 6th edition. New York, NY: Wiley-Liss, 2002.
19. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5- chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
21. Masaki T, Ohkawa S, Amano A, Ueno M, Miyakawa K, Tarao K. Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer 2005;103:1026-35.
22. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xeno- grafts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000;43:828-36.
23. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60.
24. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839-46.
25. Taouli B, Martin AJ, Qayyum A, Merriman RB, Vigneron D, Yeh BM, et al. Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol 2004;183:677-80.
26. Murtz P, Flacke S, Traber F, van den Brink JS, Gieseke J, Schild HH. Abdomen: diffusion-weighted MR imaging with pulse-triggered single-shot sequences. Radiology 2002;224:258-64.
27. Herneth AM, Philipp MO, Naude J, Funovics M, Beichel RR, Bammer R, et al. Vertebral metastases: assessment with apparent diffusion coefficient. Radiology 2002;225:889-94.
28. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo- planar MR imaging. Radiology 1999;210:617-23.
29. van Rijswijk CS, Kunz P, Hogendoorn PC, Taminiau AH, Doornbos J, Bloem JL. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging 2002;15:302-7.
30. Masui T, Katayama M, Kobayashi S, Shimizu S. MR imaging of primary malignant lymphoma of the pancreas. Radiat Med 2005;23:213-5.
31. Battula N, Srinivasan P, Prachalias A, Rela M, Heaton N. Primary pancreatic lymphoma: diagnostic and therapeutic dilemma. Pancreas 2006;33:192-4.